| Pharmaceutical Information |
| Drug Name |
Ticlopidine hydrochloride |
| Drug ID |
BADD_D02216 |
| Description |
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. |
| Indications and Usage |
Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
|
| Marketing Status |
approved |
| ATC Code |
B01AC05 |
| DrugBank ID |
DB00208
|
| KEGG ID |
D01028
|
| MeSH ID |
D013988
|
| PubChem ID |
65335
|
| TTD Drug ID |
D05LBU
|
| NDC Product Code |
49706-0331; 55486-1565; 12660-0501 |
| UNII |
A1L4914FMF
|
| Synonyms |
Ticlopidine | Ticlopidine Hydrochloride | Hydrochloride, Ticlopidine | Ticlodix | Ticlodone | 53-32C | 53 32C | 5332C | Ticlid |
|
| Chemical Information |
| Molecular Formula |
C14H15Cl2NS |
| CAS Registry Number |
53885-35-1 |
| SMILES |
C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
